Lymphoma by Site — Trials

Lymphoma by Site — Trials · CancerIndex

Clinical trials

Registered studies

900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 250
Recruiting: 134
Ph III recruiting: 7
Growth YoY: +20%
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (130)

clinicaltrialsPublishedShowing 51–53 of 53 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06914037	A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies(COURAGE)	recruiting	Phase 1	24	Tianjin Medical University Cancer Institute and HospitalOTHER	1	Apr 6, 2025	clinicaltrials
NCT06464861	Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma(CD19-CARNK/T)	recruiting	Phase 1	52	Second Affiliated Hospital, Zhejiang University, School of Medicine